Syngene, Zoetis ink pact to manufacture drug substance for Librela

Published On 2022-07-16 06:03 GMT | Update On 2022-07-16 06:03 GMT

Mumbai: Syngene International Limited has recently announced the signing of a 10-year agreement with leading animal health company, Zoetis, to manufacture the drug substance for Librela (bedinvetmab), a first in class monoclonal antibody used for treating osteoarthritis in dogs. Launched in Europe, the UK and Switzerland, the product won 'Best new companion animal product' by IHS Markit Connect in 2021 for its transformational impact on pain relief for canines suffering from this debilitating condition.

Syngene's collaboration with Zoetis started in 2011. Over the past 11 years, Syngene has undertaken development work on several monoclonal antibodies for use in animal health, including developing and manufacturing clinical supplies of a treatment for allergic or atopic dermatitis, now widely used, and Librela. This agreement, initially centred on Librela, paves the way for development and manufacturing of other molecules in the coming years and is expected to be worth up to US$ 500 Mn to Syngene over 10 years, subject to regulatory approvals and market demand.

Managing Director and Chief Executive Officer, Syngene International Limited, Jonathan Hunt said, "We are delighted to be expanding our partnership with Zoetis. This multi-year agreement marks an inflection point for our Development and Manufacturing Services Division and we look forward to completing the regulatory inspections that will be required. This 10-year agreement will position Syngene as a leading Contract Development and Manufacturing Organisation (CDMO) in animal health globally."

Nick Ashton, Executive Vice President and President, Global Manufacturing and Supply, Zoetis Inc., said "At Zoetis, we are committed to delivering high quality innovative solutions to our customers through our global supply network. By advancing the next stage of Librela with Syngene, we continue to build a strong global supply network for Zoetis products and fulfill our purpose to nurture the world and humankind by advancing care for animals."

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Syngene, Zoetis ink pact to manufacture drug substance for Librela

Similar News

Russia's Enteromix Cancer Vaccine Shows 100% Success in Trial, Awaits Final Nod for Public Use

Mankind Pharma wins CDSCO nod to start Phase 1 trials of Autoimmune drug candidate

India seeks to boost drug exports to semi regulated markets in Africa, Latin America, Southeast Asia

Jubilant Ingrevia appoints Sonia Dharap as Vice President - Sales, Business Development (US)

EMA warns of sharp rise in illegal medicines sold in EU

Indegene opens new center in Pune, boosts India presence

Indian medical devices share increased from 10% to 30% of domestic requirements in last 5 years: DoP Secretary

AstraZeneca announces Rs 176 crore investments in India to expand Chennai GITC